Editorial Article

The Binder Rises 22 Per Cent in Eight Years and the Test Rises 4.4 — and the Reason Is a 2013 EFSA Opinion Almost Nobody in This Market Quotes

Updated November 21, 2026

A tonne of feed mycotoxin binder cost USD 5,812 in 2025. By 2033, on the model in this piece, it will cost USD 7,104. That is 22.2 per cent more, or 2.54 per cent a year. Over the same eight years, the price of a single mycotoxin test moves from USD 14.79 to USD 15.44 — 4.4 per cent in total, or 0.54 per cent a year.

Two products, sold to the same mill, by companies that in one case literally owned both businesses, and one of them has pricing power while the other does not. The difference is not brand, scale, distribution or customer relationship. It is the existence of a published reference method, and the absence of one.

What a reference method does to a price

A mycotoxin test result is only useful if it can survive an argument. It has to survive a regulator, a customer’s specification, a shipment rejection, and on occasion a court. That means the result must derive from a procedure that is published, validated and shared — liquid chromatography with fluorescence detection for aflatoxin confirmation, liquid chromatography with tandem mass spectrometry for multi-analyte work, enzyme-linked immunosorbent assay or lateral flow for screening.

Once the method is public, three things follow in sequence. The reagent becomes comparable, because two suppliers’ kits are being measured against the same procedure. The buyer acquires substitutability, because a plate from one supplier can replace a plate from another without revalidating the laboratory’s entire system. And the price converges, because a comparable product with a substitutable buyer is a commodity, whatever the marketing says.

That is not a theory about this market. It is visible in the arithmetic. Of the USD 1.02 billion that mycotoxin testing adds between 2025 and 2033, USD 917.1 million — 89.9 per cent — is more tests, and only USD 102.9 million is a dearer test. The growth in testing is almost entirely a volume phenomenon.

The binder sits under no such discipline

A mycotoxin binder is authorised under Regulation (EC) No 1831/2003 as a technological additive, in a functional group formally described as substances for reduction of the contamination of feed by mycotoxins. Authorisation requires both a safety assessment and an efficacy assessment from the European Food Safety Authority. It is the second of those that matters commercially.

In 2013 the FEEDAP panel assessed a preparation of bentonite and sepiolite for use in all animal species. The panel concluded that the additive was safe up to a maximum concentration of 20,000 mg/kg of complete feed, that consumers of products from treated animals faced no concern from residues, and that the dust generated during handling was a risk to the people handling it. On efficacy, it concluded that there was insufficient evidence to conclude that the product was effective as a substance for reduction of contamination of feed with mycotoxins, on the basis of a single in vivo study in chickens.

That opinion is about one product and one submission, and it would be wrong to generalise it into a claim that no binder works. What generalises is the structure. The regulatory framework in this category establishes that a binder is safe. It does not establish that it works. There is no certified reference material, no reference method and no standard unit of effect against which a claimed reduction could be measured in a specific customer’s feed.

A buyer who cannot verify effect buys on trust: on trial data from a comparable farm, on a technical representative’s recommendation, on the reputation of a supplier who turned up in a bad harvest year and helped. Trust is not comparable line by line on a specification sheet, which means it is not substitutable, which means it does not converge in price. Where the method is free, the price is free with it. Where the claim is unfalsifiable, the claim is the product.

The chemistry makes the claim necessary

There is a second reason the mitigation side sells programmes rather than products, and it is chemical rather than commercial. Mineral adsorbents bind toxins physically, and binding depends on the shape of the molecule. Aflatoxin B1 is planar and relatively polar, so it fits into the interlayer space of a smectite clay and is held there. Deoxynivalenol and zearalenone are less planar and less favourably shaped, which is why clays that perform well against aflatoxin perform poorly against them. That is not a formulation gap that better marketing can close; it is a property of the molecules.

So no single agent covers the spectrum of toxins present in a bad harvest. The correct commercial answer is a blend, segmented by species, by region and by the toxin profile expected in a given season — clay for the aflatoxin, yeast cell wall fractions for a different range, and increasingly enzymatic biotransformers that change the toxin rather than hold it. Fumonisin esterase hydrolyses fumonisins into less toxic metabolites; microbial de-epoxidation attacks the trichothecene ring that carries the toxicity of deoxynivalenol and the T-2 toxins. These are the products that address precisely what clays cannot, and they are sold on mechanism rather than on surface.

Formulation plus advice plus a mechanism is an offer that carries margin, because it cannot be compared line by line. That is the 2.54 per cent.

What the two halves look like side by side

Measure 2025 2033 Change
Mycotoxin testing, market value USD 1.42bn USD 2.44bn 7.00% a year
Tests run 96.0m 158.0m 6.43% a year
Value of one test USD 14.79 USD 15.44 +4.4% in total
Feed binder, market value USD 1.86bn USD 3.36bn 7.67% a year
Binder tonnage 320,000 t 473,000 t 5.01% a year
Value of one tonne USD 5,812 USD 7,104 +22.2% in total
Combined market USD 3.28bn USD 5.80bn 7.39% a year

Read the unit rows first, because they invert the obvious conclusion. Binder tonnage grows more slowly than test volume — 5.01 per cent against 6.43 per cent. The testing market adds units faster than the binder market does. What it does not do is get paid more for them.

Growth 2025–2033 From more volume From price and mix Volume share
Mycotoxin testing USD 917.1m USD 102.9m 89.9%
Feed mycotoxin binders USD 889.3m USD 610.7m 59.3%
Combined USD 1,806.4m USD 713.6m 71.7%

The combined figure — 71.7 per cent volume, 28.3 per cent price — looks like a well-behaved market. It is an average of two markets that behave in opposite ways, and the average hides the finding that matters.

The asymmetry that decides how a mill behaves

There is a third consequence, and it is the one that explains why the binder market can grow without the test market’s permission.

At the 2025 realised values, one test costs USD 14.79. A tonne of binder costs USD 5,812, which at dosing rates typical of the category works out to roughly USD 5.81 of binder per tonne of finished feed. For the price of a single test, a mill can dose binder into about 2.5 tonnes of feed.

That is the substitutive margin, and it is wide. The test is a discrete, visible, per-lot purchase that produces a document and requires somebody to decide to buy it. The binder is a per-tonne premium that is small against the value of the feed and can be written into a formulation matrix without anyone raising a purchase order. A quality manager who binds prophylactically never has to have the conversation about what the result would have been.

This is why the two purchases are not made by the same logic even when they are made by the same person. The test has to be justified against doing nothing, which is free at the moment of decision. The binder has to be justified against a risk that nobody can quantify, which is easy. Both are defensive purchases, and only one of them is easy to standardise — and a defensive purchase that can be standardised will be.

What would break the price

The forecast here is not fragile in the way it looks. Hold the price of a test flat at USD 14.79 through 2033 and the combined market reaches USD 5.70 billion instead of USD 5.80 billion — a compound rate of 7.15 per cent rather than 7.39. Almost nothing happens.

Hold the binder price flat instead, and the combined market reaches USD 5.19 billion at 5.90 per cent. Hold every price flat and it reaches USD 5.09 billion at 5.64 per cent. The entire price story in this market is worth about 175 basis points of compound growth, and almost all of it sits on the additive side.

Which means the number to watch is not the price of a test. It is the efficacy question. If a major jurisdiction were to establish a reference method and certified materials for binder efficacy — even one — the products would become comparable, the differentiation premium would compress, and the price contribution on the mitigation side would move toward the testing side’s 10 per cent rather than staying near 41. Nothing in the authorisation pipeline examined for this analysis signals that it is coming. But it is the assumption on which the whole forecast rests, and a reader who disagrees with one thing in this piece should disagree with that.

Until then, the market will keep doing what the arithmetic describes: selling more tests at almost the same price, and selling a moderately larger tonnage of binder at a meaningfully higher one.

Figures in this article are drawn from Global Mycotoxin Testing & Feed Binder Market Report, Size, Share and Forecast 2026–2033, published by Pheonix Research. Both the value base and the unit line are Pheonix constructs rather than reported disclosures; the value base carries a range of USD 2.95 billion to USD 3.65 billion. The EFSA opinion referred to is the FEEDAP Panel’s assessment of a bentonite-and-sepolite preparation, EFSA Journal 2013;11(4):3179.

Frequently Asked Questions

How much does a mycotoxin binder cost compared with a mycotoxin test?

The realised price of a tonne of feed mycotoxin binder rises from USD 5,812 in 2025 to USD 7,104 in 2033, a rise of 22.2 per cent or 2.54 per cent a year. Over the same period the realised value of a single mycotoxin test moves from USD 14.79 to USD 15.44, a rise of 4.4 per cent or 0.54 per cent a year. Both figures are Pheonix constructs derived from the value and volume lines in the report, not company disclosures.

Why does the binder price rise faster than the test price?

Because a test is anchored to a published reference method and a binder is not. Where the method is public and shared, reagents are comparable, buyers can substitute one supplier for another, and price converges. Where no certified measure of efficacy exists, products are differentiated by formulation, trial data and advisory support instead — and that differentiation carries margin.

What did EFSA actually conclude about binder efficacy?

In 2013 EFSA's FEEDAP panel assessed a bentonite-and-sepolite preparation for all animal species and concluded that it was safe up to 20,000 mg/kg of complete feed, but that there was insufficient evidence to conclude on its efficacy as a substance for reduction of contamination of feed with mycotoxins, on the basis of a single in vivo study in chickens. That opinion concerns one product; what generalises is that the authorisation establishes safety rather than efficacy.

What happens to the forecast if binder prices stop rising?

Hold the binder price flat at its 2025 level and the combined market reaches USD 5.19 billion in 2033 rather than USD 5.80 billion, a compound rate of 5.90 per cent instead of 7.39. Hold every price flat and it reaches USD 5.09 billion at 5.64 per cent. The entire price contribution is worth about 175 basis points of compound growth, and almost all of it sits on the additive side.